Katerina Hatzi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10652188/publications.pdf

Version: 2024-02-01

34 papers	2,541 citations	361413 20 h-index	501196 28 g-index
34 all docs	34 docs citations	34 times ranked	4245 citing authors

#	Article	IF	Citations
1	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nature Immunology, 2019, 20, 86-96.	14.5	71
2	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discovery, 2017, 7, 506-521.	9.4	43
3	CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discovery, 2017, 7, 38-53.	9.4	218
4	Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status. Clinical Immunology, 2016, 172, 44-51.	3.2	11
5	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell, 2016, 30, 197-213.	16.8	200
6	Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. Immunity, 2016, 45, 497-512.	14.3	112
7	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. Journal of Clinical Investigation, 2016, 126, 3351-3362.	8.2	133
8	Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget, 2016, 7, 3520-3532.	1.8	26
9	BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms. Journal of Experimental Medicine, 2015, 212, 539-553.	8.5	218
10	The BCL6 RD2 Domain Governs Commitment of Activated B Cells to Form Germinal Centers. Cell Reports, 2014, 8, 1497-1508.	6.4	67
11	Interferon Regulatory Factor 8 (IRF8) Interacts with the B Cell Lymphoma 6 (BCL6) Corepressor BCOR. Journal of Biological Chemistry, 2014, 289, 34250-34257.	3.4	13
12	Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends in Molecular Medicine, 2014, 20, 343-352.	6.7	148
13	BCL6 Orchestrates Tfh Differentiation Via Multiple Distinct Mechanisms. Blood, 2014, 124, 4137-4137.	1.4	1
14	A Hybrid Mechanism of Action for BCL6 in B Cells Defined by Formation of Functionally Distinct Complexes at Enhancers and Promoters. Cell Reports, 2013, 4, 578-588.	6.4	161
15	Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nature Immunology, 2013, 14, 380-388.	14.5	111
16	Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood, 2013, 121, 4271-4279.	1.4	32
17	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. Blood, 2013, 122, 1-1.	1.4	23
18	The Histone Demethylase LSD1 Acts As a BCL6 Corepressor In Germinal Center B Cells. Blood, 2013, 122, 781-781.	1.4	6

#	Article	IF	Citations
19	Three-Dimensional Reorganization of the Genome During B Cell Affinity Maturation. Blood, 2012, 120, 279-279.	1.4	0
20	Enhancer Profiling Reveals SOX9 As a Novel Transcription Regulator of B Cell Activation and DLBCL Transformation. Blood, 2012, 120, 527-527.	1.4	0
21	BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. Journal of Experimental Medicine, 2011, 208, 2163-2174.	8.5	154
22	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. Journal of Clinical Investigation, 2010, 120, 4569-4582.	8.2	101
23	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6â€“dependent B cell lymphomas. Nature Medicine, 2009, 15, 1369-1376.	30.7	149
24	A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood, 2009, 113, 3397-3405.	1.4	154
25	Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood, 2009, 114, 3615-3624.	1.4	37
26	Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood, 2008, 112, 5122-5129.	1.4	152
27	Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation. Molecular Medicine, 2008, 14, 665-674.	4.4	174
28	A Different Ontogenesis for CLL Cases Carrying Stereotyped Antigen Receptors: Molecular and Computational Evidence. Blood, 2008, 112, 777-777.	1.4	0
29	B-CLL Antibodies Encoded by Stereotypic VH1-69, D3-16, and JH3 Rearrangements Immunoprecipitate Non-Muscle Myosin Heavy Chain IIA.. Blood, 2007, 110, 739-739.	1.4	0
30	Binding of CLL B-Cell Receptors to Viable and Apoptotic Human Cells Offers Insight into the Role of Autoantigens in Leukemic Transformation.. Blood, 2007, 110, 741-741.	1.4	0
31	B-Cell Chronic Lymphocytic Leukemia (B-CLL) Cells Express Antibodies Reactive with Antigenic Epitopes Expressed on the Surface of Common Bacteria.. Blood, 2006, 108, 25-25.	1.4	13
32	Polyreactive Monoclonal Antibodies Synthesized by Some B-CLL Cells Recognize Specific Antigens on Viable and Apoptotic T Cells.. Blood, 2006, 108, 2813-2813.	1.4	11
33	B-CLL Antibodies Comprised of Stereotypic VH1-69, D3-16, and JH3 Rearrangements Immunoprecipitate Cellular Protein(s).. Blood, 2006, 108, 2816-2816.	1.4	2
34	IGHV Gene Replacement in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Occurs at a Frequency Similar to That in Normal B Cells and May Augment Clonal Expansion by Permitting Autogenic/Microbial Clonal Stimulation.. Blood, 2006, 108, 2086-2086.	1.4	0